| 注册
首页|期刊导航|数字中医药(英文)|补脾益气疗法联合甲状腺激素治疗桥本氏甲状腺功能减退症的疗效与安全性:系统综述与meta分析

补脾益气疗法联合甲状腺激素治疗桥本氏甲状腺功能减退症的疗效与安全性:系统综述与meta分析

杨梦菲 赖倚文 高天舒

数字中医药(英文)2025,Vol.8Issue(3):335-350,16.
数字中医药(英文)2025,Vol.8Issue(3):335-350,16.DOI:10.1016/j.dcmed.2025.09.006

补脾益气疗法联合甲状腺激素治疗桥本氏甲状腺功能减退症的疗效与安全性:系统综述与meta分析

Efficacy and safety of the tonifying spleen and reinforcing Qi therapy combined with thyroid hormone in Hashimoto's hypothyroidism:a systematic review and meta-analysis

杨梦菲 1赖倚文 2高天舒2

作者信息

  • 1. 辽宁中医药大学研究生院,辽宁 沈阳 110847,中国
  • 2. 辽宁中医药大学附属医院内分泌科,辽宁 沈阳 110032,中国
  • 折叠

摘要

Abstract

Objective To evaluate the effectiveness and safety of the tonifying spleen and reinforcing Qi(TSRQ)therapy combined with thyroid hormone replacement therapy(THRT)for treating Hashimoto's hypothyroidism. Methods From database foundation to January 14,2025,PubMed,Web of Science,Cochrane,Embase,China National Knowledge Infrastructure(CNKI),Wanfang Data,China Science and Technology Journal Database(VIP),and China Biomedical Literature Database(CBM)were searched for relevant information.Randomized clinical trials(RCTs)evaluating the efficacy and safety of TSRQ therapy combined with THRT for Hashimoto's hypothyroidism were eligi-ble for inclusion.Following quality assessment,data were analyzed using Stata 15.1 to con-duct a meta-analysis and systematic review.Subgroup analysis was used to identify the sources of heterogeneity.The Grading of Recommendations Assessment,Development and Evaluation(GRADE)system was adopted to evaluate the certainty of the evidence. Results This study included 30 RCTs,comprising 2 687 patients with Hashimoto's hypothy-roidism.Overall methodological quality was acceptable,with no studies exhibiting a high risk of bias.Meta-analysis demonstrated that TSRQ therapy combined with THRT significantly enhanced serum free triiodothyronine(fT3)levels[standardized mean difference(SMD)=0.76,95%confidence interval(CI):0.57 to 0.94,P<0.001]and free thyroxine(fT4)levels(SMD=0.86,95%CI:0.61 to 1.11,P<0.001),while reducing thyroid-stimulating hormone(TSH)lev-els(SMD=-0.99,95%CI:-1.20 to-0.78,P<0.001)compared with THRT alone.Further-more,the combination therapy significantly decreased anti-thyroid peroxidase antibody(TPOAb)levels(SMD=-1.46,95%CI:-1.79 to-1.13,P<0.001)and anti-thyroglobulin anti-body(TgAb)levels(SMD=-1.46,95%CI:-1.80 to-1.11,P<0.001).TSRQ therapy did not adversely impact the safety profile of THRT.However,while some sources of heterogeneity have been identified(e.g.,specific detection methodologies,I²=0.0%,P=0.938),there re-mains a portion of unexplained heterogeneity(e.g.,publication year,I²=93.4%,P<0.001),which has undermined confidence in these pooled estimates.The evidence ratings for fT3,fT4,and TSH were limited,and those for TPOAb and TgAb were even more limited. Conclusion TSRQ therapy combined with THRT may strengthen thyroid function and modu-late immune dysregulation in patients with Hashimoto's hypothyroidism without increasing adverse event incidence.

关键词

桥本氏甲状腺功能减退症/补脾益气疗法/中医/系统评价/meta分析

Key words

Hashimoto's hypothyroidism/Tonifying spleen and reinforcing/Qi therapy/Traditional Chinese medicine/Systematic review/Meta-analysis

引用本文复制引用

杨梦菲,赖倚文,高天舒..补脾益气疗法联合甲状腺激素治疗桥本氏甲状腺功能减退症的疗效与安全性:系统综述与meta分析[J].数字中医药(英文),2025,8(3):335-350,16.

基金项目

Project of Liaoning Provincial Science&Technology De-partment(2023-MSLH-189),and National Natural Sci-ence Foundation of China(82174359). (2023-MSLH-189)

数字中医药(英文)

2096-479X

访问量0
|
下载量0
段落导航相关论文